We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current EYPT market cap is 974.19M. The company's latest EPS is USD -1.4207 and P/E is -13.89.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 10.01M | 10.53M | 7.68M | 9.11M | 15.2M |
| Operating Income | -18.4M | -43.74M | -21.55M | -22.23M | -14.93M |
| Net Income | -18.42M | -43.45M | -21.16M | -22.92M | -12.61M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 20.37M | 34.44M | 36.94M | 41.4M | 46.02M |
| Operating Income | -47.86M | -37.29M | -55.28M | -99.64M | -75.07M |
| Net Income | -56.79M | -45.39M | -58.42M | -102.25M | -70.8M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 220.49M | 180.36M | 154.59M | 175.66M | 160.04M |
| Total Liabilities | 84.14M | 83.99M | 76.2M | 118.39M | 101.42M |
| Total Equity | 136.35M | 96.37M | 78.39M | 57.26M | 58.62M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 72.97M | 91.72M | 263.37M | 180.36M | 355.18M |
| Total Liabilities | 64.64M | 73.18M | 78.99M | 83.99M | 88.86M |
| Total Equity | 8.33M | 18.54M | 184.38M | 96.37M | 266.32M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -52.42M | -65.01M | -16.84M | 40.19M | 24.98M |
| Investing | -50.18M | -17.27M | 32.09M | 45.55M | 43.83M |
| Financing | -632k | -690k | -5.12M | -41.78M | -31.42M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -56.7M | -14.44M | -50.1M | -65.01M | 1.88M |
| Investing | -213k | -362k | -33.12M | -17.27M | -3.32M |
| Financing | 33.86M | 37.49M | 216.9M | -690k | 187.07M |
| Market Cap | 974.19M |
| Price to Earnings Ratio | -13.89 |
| Price to Sales Ratio | 21.38 |
| Price to Cash Ratio | 3.5 |
| Price to Book Ratio | 3.69 |
| Dividend Yield | - |
| Shares Outstanding | 49.83M |
| Average Volume (1 week) | 1.17M |
| Average Volume (1 Month) | 1.02M |
| 52 Week Change | 164.91% |
| 52 Week High | 30.99 |
| 52 Week Low | 5.67 |
| Spread (Intraday) | 0.45 (2.31%) |
| Company Name | EyePoint Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.eyepointpharma.com |
| Industry | lab analytical instruments (3826) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
